Biocon’s new Malaysian plant, where the Indian biotech heavyweight is making its insulin biosimilar that is a challenger to Sanofi’s blockbuster Lantus, has cleared a key regulatory hurdle. The facility, Asia’s largest integrated insulins plant, has received a certificate of good manufacturing practice from European regulators that Biocon said will help the company supply the EU diabetes market “even more aggressively.”
Biocon founder and chief executive Kiran Mazumdar-Shaw also said she is open to private-equity investment ahead of the firm’s planned...




